FDA places Alzheimer’s therapeutic IND Application on hold

The FDA has placed a hold on the Investigational New Drug (IND) application for DNL919, indicating they will provide an official clinical hold letter to Denali Therapeutics in approximately 30 days. Denali had hoped to begin fist-in-human clinical trials for its therapeutic DNL919, under development for the treatment of Alzheimer’s disease (AD).

read more